tbuckley/cabot-search huggingface dataset:
Mucoadhesive film for oral delivery of vaccines for protection of the respiratory tract
Authors: Hana Esih, Klemen Mezgec, Martina Billmeier, Špela Malenšek, Mojca Benčina, Blaž Grilc, Sara Vidmar, Mirjana Gašperlin, Marjan Bele, Mihaela Zidarn, Tatjana Lejko Zupanc, Tina Morgan, Ingo Jordan, Volker Sandig, Silke Schrödel, Christian Thirion, Ulrike Protzer, Ralf Wagner, Duško Lainšček, Roman Jerala
Journal: Journal of Controlled Release (2024)

The delivery of vaccines plays a pivotal role in influencing the strength and longevity of the immune response and controlling reactogenicity. Mucosal immunization, as compared to parenteral vaccination, could offer greater protection against respiratory infections while being less invasive. While oral vaccination has been presumed less effective and believed to target mainly the gastrointestinal tract, trans-buccal delivery using mucoadhesive films (MAF) may allow targeted delivery to the mucosa. Here we present an effective strategy for mucosal delivery of several vaccine platforms incorporated in MAF, including DNA plasmids, viral vectors, and lipid nanoparticles incorporating mRNA (mRNA/LNP). The mRNA/LNP vaccine formulation targeting SARS-CoV-2 as a proof of concept remained stable within MAF consisting of slowly releasing water-soluble polymers and an impermeable backing layer, facilitating enhanced penetration into the oral mucosa. This formulation elicited antibody and cellular responses comparable to the intramuscular injection, but also induced the production of mucosal IgAs, highlighting its efficacy, particularly for use as a booster vaccine and the potential advantage for protection against respiratory infections. The MAF vaccine preparation demonstrates significant advantages, such as efficient delivery, stability, and simple noninvasive administration with the potential to alleviate vaccine hesitancy.
Responding to the global epidemic of amphetamine-type stimulant use compromising biomedical HIV prevention among men who have sex with men
Authors: Adam W Carrico, Leah Davis Ewart, Udi Davidovich, Lisa Maher, Kai J Jonas, Keith J Horvath, Sabina Hirshfield, Thomas E Guadamuz, Tara Carney, Christian Grov
Journal: The Lancet HIV (2024)
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
Authors: Yi Lin, Lugui Qiu, Saad Usmani, Chng Wee Joo, Luciano Costa, Benjamin Derman, Juan Du, Hermann Einsele, Carlos Fernandez de Larrea, Roman Hajek, P Joy Ho, Efstathios Kastritis, Joaquin Martinez-Lopez, Maria-Victoria Mateos, Joseph Mikhael, Philippe Moreau, Chandramouli Nagarajan, Ajay Nooka, Michael O'Dwyer, Fredrik Schjesvold, Surbhi Sidana, Niels WCJ van de Donk, Katja Weisel, Sonja Zweegman, Noopur Raje, Paula Rodriguez Otero, Larry D Anderson, Shaji Kumar, Tom Martin
Journal: The Lancet Oncology (2024)
Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system
Authors: Alex K Bryant, Jacqueline R Lewy, R Daniel Bressler, Zoey Chopra, Derek J Gyori, Brian G Bazzell, Julie A Moeller, Sofia I Jacobson, A Mark Fendrick, Eve A Kerr, Nithya Ramnath, Michael D Green, Timothy P Hofer, Parth Vaishnav, Garth W Strohbehn
Journal: The Lancet Oncology (2024)
Putting patient safety first: a global imperative
Authors: None The Lancet Oncology
Journal: The Lancet Oncology (2024)

On April 18, 2024, WHO launched the first ever Patient Safety Rights Charter to delineate patient rights regarding health and safety and to support the formulation of policies and guidelines for patient-centred health-care systems. The Charter includes ten rights that are fundamental to reducing inadvertent harm to patients, including the right to timely, effective, and appropriate care and the right to safe health-care processes and practices. In ever evolving cancer care, among the challenges of changing government policies, regulatory delays, and staff and drug shortages, a steadfast commitment to patient safety and wellbeing is paramount.
Correction to Lancet Oncol 2023; 24: 1002–17
Journal: The Lancet Oncology (2024)

In this Review, the abbreviation of "homologous recombination deficiency" should have been HRd throughout, and in the third paragraph of the Observations of withdrawals of drug approvals based on trials with surrogate primary endpoints section, the fifth sentence of this paragraph should have read "An unpowered analysis for patients with homologous recombination proficient tumours showed a median progressionfree survival of 8•4 months in the niraparib group versus 5•4 months in the placebo group (HR 0•65, 95% CI 0•49-0•87)".This correction has been made to the online version as of May 28, 2024.
Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study
Authors: Maria Salgado, Cristina Gálvez, Monique Nijhuis, Mi Kwon, E Fabian Cardozo-Ojeda, Jon Badiola, Matthew J Gorman, Laura E P Huyveneers, Victor Urrea, Alessandra Bandera, Björn-Erik Ole Jensen, Linos Vandekerckhove, Manuel Jurado, Kavita Raj, Julian Schulze zur Wiesch, Rebeca Bailén, Johanna M Eberhard, Mitja Nabergoj, Gero Hütter, Raquel Saldaña-Moreno, Sharon Oldford, Lisa Barrett, Maria Luisa Montes Ramirez, Salisu Garba, Ravi Kumar Gupta, Boris Revollo, Christelle Ferra-Coll, Jurgen Kuball, Galit Alter, Asier Sáez-Cirión, Jose Luis Diez-Martin, Elizabeth R Duke, Joshua T Schiffer, Annemarie Wensing, Javier Martinez-Picado, Antonio Muscatello, Alexandra Calmy, Anais Chapel, Anne-Claire Mamez, Caroline Passaes, Clarissa Brisseau, Eduardo Olivarria, Elena Knops, Eva Heger, Fatima Bikhezar, Federico Perdomo-Celis, Guido Kobbe, Ian H Gabriel, Jan V Lunzen, Judith Dalmau, Luz Martín-Carbonero, Mari Carmen Puertas, Mari Carmen Garcia-Guerrero, Marie-Angélique de Scheerder, Mathieu Angin, Nadine Lübke, Pascual Balsalobre, Raquel de Paz, Rolf Kaiser, Tessa Kerre, Thomas Harrer, Tom Luedde, Vanderson Rocha
Journal: The Lancet HIV (2024)
Sex workers are a key population in society
Authors: None The Lancet HIV
Journal: The Lancet HIV (2024)

On June 2, 1975, a group of about 100 sex workers took over the Saint-Nizier Church in Lyon, France, to protest their living conditions and treatment by authorities, hanging banners from the church spire declaiming "Our children do not want their mothers to go to jail". The protestors called for an end to police harassment, reopening of hotels where they worked, and proper investigation into a series of murders of sex workers. Their cause sparked further protests across France, and garnered international attention.
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Authors: Moritz Fürstenau, Arnon P Kater, Sandra Robrecht, Julia von Tresckow, Can Zhang, Michael Gregor, Patrick Thornton, Philipp B Staber, Tamar Tadmor, Vesa Lindström, Gunnar Juliusson, Ann Janssens, Mark-David Levin, Caspar da Cunha-Bang, Christof Schneider, Neta Goldschmidt, Elisabeth Vandenberghe, Davide Rossi, Rudolf Benz, Thomas Nösslinger, Daniel Heintel, Christian B Poulsen, Ilse Christiansen, Henrik Frederiksen, Lisbeth Enggaard, Eduardus F M Posthuma, Djamila E Issa, Hein P J Visser, Mar Bellido, Nadine Kutsch, Jan Dürig, Alexander Stehle, Matthias Vöhringer, Sebastian Böttcher, Clemens Schulte, Florian Simon, Anna-Maria Fink, Kirsten Fischer, Emily E Holmes, Karl-Anton Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Michael Hallek, Carsten U Niemann, Barbara Eichhorst
Journal: The Lancet Oncology (2024)

In the primary analysis report of the GAIA/CLL13 trial, we found that venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib improved undetectable measurable residual disease (MRD) rates and progression-free survival compared with chemoimmunotherapy in patients with previously untreated chronic lymphocytic leukaemia. However, to our knowledge, no data on direct comparisons of different venetoclax-based combinations are available.
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial
Authors: Cissy Kityo, Ivan K Mambule, Joseph Musaazi, Simiso Sokhela, Henry Mugerwa, Gilbert Ategeka, Fiona Cresswell, Abraham Siika, Josphat Kosgei, Reena Shah, Logashvari Naidoo, Kimton Opiyo, Caroline Otike, Karlien Möller, Arvind Kaimal, Charity Wambui, Veerle Van Eygen, Perry Mohammed, Fafa Addo Boateng, Nicholas I Paton
Journal: The Lancet Infectious Diseases (2024)
Correction to Lancet Oncol 2024; 25: e126–35
Journal: The Lancet Oncology (2024)

In this Review, the abbreviation of "homologous recombination deficiency" should have been HRd throughout, and in the third paragraph of the Observations of withdrawals of drug approvals based on trials with surrogate primary endpoints section, the fifth sentence of this paragraph should have read "An unpowered analysis for patients with homologous recombination proficient tumours showed a median progressionfree survival of 8•4 months in the niraparib group versus 5•4 months in the placebo group (HR 0•65, 95% CI 0•49-0•87)".This correction has been made to the online version as of May 28, 2024.
Addressing challenges in low-income and middle-income countries through novel radiotherapy research opportunities
Authors: May Abdel-Wahab, C Norman Coleman, Jesper Grau Eriksen, Peter Lee, Ryan Kraus, Ekaterina Harsdorf, Becky Lee, Adam Dicker, Ezra Hahn, Jai Prakash Agarwal, Pataje G S Prasanna, Michael MacManus, Paul Keall, Nina A Mayr, Barbara Alicja Jereczek-Fossa, Francesco Giammarile, In Ah Kim, Ajay Aggarwal, Grant Lewison, Jiade J Lu, Douglas Guedes de Castro, Feng-Ming Spring Kong, Haidy Afifi, Hamish Sharp, Verna Vanderpuye, Tajudeen Olasinde, Fadi Atrash, Luc Goethals, Benjamin W Corn
Journal: The Lancet Oncology (2024)
The burden of cardiovascular disease and risk for subsequent major adverse cardiovascular events in survivors of childhood cancer: a prospective, longitudinal analysis from the St Jude Lifetime Cohort Study
Authors: Rawan A Hammoud, Qi Liu, Stephanie B Dixon, Aron Onerup, Daniel A Mulrooney, I-Chan Huang, John L Jefferies, Isaac B Rhea, Kirsten K Ness, Matthew J Ehrhardt, Melissa M Hudson, Bonnie Ky, Nickhill Bhakta, Yadav Sapkota, Yutaka Yasui, Gregory T Armstrong
Journal: The Lancet Oncology (2024)
Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics
Authors: Andrew M Scott, Brian M Zeglis, Suzanne E Lapi, Peter J H Scott, Albert D Windhorst, May Abdel-Wahab, Francesco Giammarile, Diana Paez, Amirreza Jalilian, Peter Knoll, Aruna Korde, Shrikant Vichare, Nayyereh Ayati, Sze Ting Lee, Serge K Lyashchenko, Jingjing Zhang, Jean Luc Urbain, Jason S Lewis
Journal: The Lancet Oncology (2024)
Pseudoxanthoma elasticum – Genetics, pathophysiology, and clinical presentation
Authors: Kristina Pfau, Imre Lengyel, Jeannette Ossewaarde-van Norel, Redmer van Leeuwen, Sara Risseeuw, Georges Leftheriotis, Hendrik P.N. Scholl, Nicolas Feltgen, Frank G. Holz, Maximilian Pfau
Journal: Progress in Retinal and Eye Research (2024)

Pseudoxanthoma elasticum (PXE) is an autosomal-recessively inherited multisystem disease. Mutations in the ABCC6-gene are causative, coding for a transmembrane transporter mainly expressed in hepatocytes, which promotes the efflux of adenosine triphosphate (ATP). This results in low levels of plasma inorganic pyrophosphate (PPi), a critical anti-mineralization factor. The clinical phenotype of PXE is characterized by the effects of elastic fiber calcification in the skin, the cardiovascular system, and the eyes. In the eyes, calcification of Bruch's membrane results in clinically visible lesions, including peau d'orange, angioid streaks, and comet tail lesions. Frequently, patients must be treated for secondary macular neovascularization. No effective therapy is available for treating the cause of PXE, but several promising approaches are emerging. Finding appropriate outcome measures remains a significant challenge for clinical trials in this slowly progressive disease. This review article provides an in-depth summary of the current understanding of PXE and its multi-systemic manifestations. The article offers a detailed overview of the ocular manifestations, including their morphological and functional consequences, as well as potential complications. Lastly, previous and future clinical trials of causative treatments for PXE are discussed.
Recent advances and impending challenges for the radiopharmaceutical sciences in oncology
Authors: Suzanne E Lapi, Peter J H Scott, Andrew M Scott, Albert D Windhorst, Brian M Zeglis, May Abdel-Wahab, Richard P Baum, John M Buatti, Francesco Giammarile, Ana P Kiess, Amirreza Jalilian, Peter Knoll, Aruna Korde, Jolanta Kunikowska, Sze Ting Lee, Diana Paez, Jean-Luc Urbain, Jingjing Zhang, Jason S Lewis
Journal: The Lancet Oncology (2024)
Production and regulatory issues for theranostics
Authors: Francesco Giammarile, Diana Paez, Richard Zimmermann, Cathy S Cutler, Amirreza Jalilian, Aruna Korde, Peter Knoll, Nayyereh Ayati, Jason S Lewis, Suzanne E Lapi, Roberto C Delgado Bolton, Jolanta Kunikowska, Enrique Estrada Lobato, Jean-Luc Urbain, Ola Holmberg, May Abdel-Wahab, Andrew M Scott
Journal: The Lancet Oncology (2024)
A genome-wide meta-analysis of palmoplantar pustulosis implicates TH2 responses and cigarette smoking in disease pathogenesis
Authors: Ariana Hernandez-Cordero, Laurent Thomas, Alice Smail, Zhao Qin Lim, Jake R. Saklatvala, Raymond Chung, Charles J. Curtis, Patrick Baum, Sudha Visvanathan, A. David Burden, Hywel L. Cooper, Giles Dunnill, Christopher E.M. Griffiths, Nick J. Levell, Richard Parslew, Nick J. Reynolds, Shyamal Wahie, Richard B. Warren, Andrew Wright, Thamir Abraham, Muhmad Ali, Suzannah August, David Baudry, Gabrielle Becher, Anthony Bewley, Victoria Brown, Victoria Cornelius, Sharizan Ghaffar, John Ingram, Svetlana Kavakleiva, Susan Kelly, Mohsen Khorshid, Helen Lachmann, Effie Ladoyanni, Helen McAteer, John McKenna, Freya Meynell, Prakash Patel, Andrew Pink, Kingsley Powell, Angela Pushparajah, Catriona Sinclair, Rachel Wachsmuth, Michael Simpson, Kristian Hveem, Jonathan N. Barker, Nick Dand, Mari Løset, Catherine H. Smith, Francesca Capon
Journal: Journal of Allergy and Clinical Immunology (2024)

Background Palmoplantar pustulosis (PPP) is an inflammatory skin disorder that mostly affects smokers and manifests with painful pustular eruptions on the palms and soles. While the disease can present with concurrent plaque psoriasis, TNF and IL-17/IL-23 inhibitors show limited efficacy. There is therefore a pressing need to uncover PPP disease drivers and therapeutic targets. Objectives To identify genetic determinants of PPP and investigate whether cigarette smoking contributes to disease pathogenesis. Methods We performed a genome-wide association meta-analysis of three North-European cohorts (n=1,456 PPP cases and 402,050 controls). We then used the scGWAS program to investigate the cell-type specificity of the association signals. We also undertook genetic correlation analyses to examine the similarities between PPP and other immune-mediated diseases. Finally, we applied Mendelian randomization to analyze the causal relationship between cigarette smoking and PPP. Results We found that PPP is not associated with the main genetic determinants of plaque psoriasis. Conversely, we identified genome-wide significant associations with the FCGR3A/FCGR3B and CCHCR1 loci. We also observed 13 suggestive (P<5X10-6) susceptibility regions, including the IL4/IL13 interval. Accordingly, we demonstrated a significant genetic correlation between PPP and Th2-mediated diseases like atopic dermatitis and ulcerative colitis. We also found that genes mapping to PPP-associated intervals were preferentially expressed in dendritic cells and often implicated in T-cell activation pathways. Finally, we undertook a Mendelian randomization analysis, which supported a causal role of cigarette smoking in PPP. Conclusions The first genome-wide association study of PPP points to a pathogenic role for deregulated Th2 responses and cigarette smoking.
Parallel genomic analysis from paired bone marrow and peripheral blood samples of 200 cytopenic patients
Authors: Sandra Huber, Natalie Wossidlo, Torsten Haferlach, Stephan Hutter, Wencke Walter, Christian Pohlkamp, Isolde Summerer, Henning Ruge, Constance Baer, Gregor Hoermann, Manja Meggendorfer, Wolfgang Kern, Claudia Haferlach
Journal: Leukemia (2024)
ADP-ribosylation, a multifaceted modification: Functions and mechanisms in aging and aging-related diseases
Authors: Wu Hao, Zhao Jialong, Yuan Jiuzhi, Yu Yang, Lv Chongning, Lu jincai
Journal: Ageing Research Reviews (2024)

Aging, a complex biological process, plays key roles the development of multiple disorders referred as aging-related diseases involving cardiovascular diseases, stroke, neurodegenerative diseases, cancers, lipid metabolism-related diseases. ADP-ribosylation is a reversible modification onto proteins and nucleic acids to alter their structures and/or functions. Growing evidence support the importance of ADP-ribosylation and ADP-ribosylation-associated enzymes in aging and age-related diseases. In this review, we summarized ADP-ribosylation-associated proteins including ADP-ribosyl transferases, the ADP-ribosyl hydrolyses and ADP-ribose binding domains. Furthermore, we outlined the latest knowledge about regulation of ADP-ribosylation in the pathogenesis and progression of main aging-related diseases, organism aging and cellular senescence, and we also speculated the underlying mechanisms to better disclose this novel molecular network. Moreover, we discussed current issues and provided an outlook for future research, aiming to revealing the unknown bio-properties of ADP-ribosylation, and establishing a novel therapeutic perspective in aging-related diseases and health aging via targeting ADP-ribosylation.
4D‐Printed MXene‐Based Artificial Nerve Guidance Conduit for Enhanced Regeneration of Peripheral Nerve Injuries
Authors: Zhilong Wang, Yan Zheng, Liang Qiao, Yuanya Ma, Huajing Zeng, Jiachen Liang, Qian Ye, Kuangyu Shen, Bin Liu, Luyi Sun, Zengjie Fan
Journal: Advanced Healthcare Materials (2024)

Abstract Repairing larger defects (&gt;5 mm) in peripheral nerve injuries (PNIs) remains a significant challenge when using traditional artificial nerve guidance conduits (NGCs). A novel approach that combines 4D printing technology with poly(L‐lactide‐co‐trimethylene carbonate) (PLATMC) and Ti 3 C 2 T x MXene nanosheets is proposed, thereby imparting shape memory properties to the NGCs. Upon body temperature activation, the printed sheet‐like structure can quickly self‐roll into a conduit‐like structure, enabling optimal wrapping around nerve stumps. This design enhances nerve fixation and simplifies surgical procedures. Moreover, the integration of microchannel expertly crafted through 4D printing, along with the incorporation of MXene nanosheets, introduces electrical conductivity. This feature facilitates the guided and directional migration of nerve cells, rapidly accelerating the healing of the PNI. By leveraging these advanced technologies, the developed NGCs demonstrate remarkable potential in promoting peripheral nerve regeneration, leading to substantial improvements in muscle morphology and restored sciatic nerve function, comparable to outcomes achieved through autogenous nerve transplantation.
Responsiveness of the condition-specific Outcome measures for VAscular MAlformations (OVAMA) questionnaire to measure symptoms and appearance in patients with vascular malformations
Authors: Merel L E Stor, Max M Lokhorst, Sophie E R Horbach, Michiel A J Luijten, Phyllis I Spuls, Chantal M AM van der Horst
Journal: British Journal of Dermatology (2024)

Evidence-based guidelines for the treatment of vascular malformations (VMs) are not readily available, possibly due to the diversity in methods used to evaluate treatment efficacy in clinical research, complicating the aggregation and comparison of study results. The Outcome measures for VAscular MAlformations (OVAMA) questionnaire was developed to measure uniformly symptoms and appearance (i.e. condition-specific core outcome domains) in patients with VMs. However, the OVAMA questionnaire needs to be responsive to changes in these constructs in order to assess whether disease status has changed since treatment.
CircPDIA3/miR-449a/XBP1 feedback loop curbs pyroptosis by inhibiting palmitoylation of the GSDME-C domain to induce chemoresistance of colorectal cancer
Authors: Jiatong Lin, Zejian Lyu, Huolun Feng, Huajie Xie, Jingwen Peng, Weifu Zhang, Jun Zheng, Jiabin Zheng, Zihao Pan, Yong Li
Journal: Drug Resistance Updates (2024)

Although oxaliplatin (OXA) is widely used in the frontline treatment of colorectal cancer (CRC), CRC recurrence is commonly observed due to OXA resistance. OXA resistance is associated with a number of factors, including abnormal regulation of pyroptosis. It is therefore important to elucidate the abnormal regulatory mechanism underlying pyroptosis. Here, we identified that the circular RNA circPDIA3 played an important role in chemoresistance in CRC. CircPDIA3 could induce chemoresistance in CRC by inhibiting pyroptosis both in vitro and in vivo. Mechanistically, RIP, RNA pull-down and co-IP assays revealed that circPDIA3 directly bonded to the GSDME-C domain, subsequently enhanced the autoinhibitory effect of the GSDME-C domain through blocking the GSDME-C domain palmitoylation by ZDHHC3 and ZDHHC17, thereby restraining pyroptosis. Additionally, it was found that the circPDIA3/miR-449a/XBP1 positive feedback loop increased the expression of circPDIA3 to induce chemoresistance. Furthermore, our clinical data and patient-derived tumor xenograft (PDX) models supported the positive association of circPDIA3 with development of chemoresistance in CRC patients. Taken together, our findings demonstrated that circPDIA3 could promote chemoresistance by amplifying the autoinhibitory effect of the GSDME-C domain through inhibition of the GSDME-C domain palmitoylation in CRC. This study provides novel insights into the mechanism of circRNA in regulating pyroptosis and providing a potential therapeutic target for reversing chemoresistance of CRC.